Troponin Hook-Effect Claims: What Two 510(k)s Actually Tested

The Short Answer: Two Numbers, Two Different Experiments

If your team is planning the high-dose hook-effect study for a new troponin immunoassay, the public 510(k) record offers two very different-looking reference points. Roche's 510(k) summary for the Elecsys Troponin T Gen 5 STAT assay (K162895) reports: "No hook effect was seen up to 100,000 ng/L". Abbott's 510(k) summary for the i-STAT hs-TnI cartridge with the i-STAT Alinity System (K253051) reports that hook effect "was not observed ... up to approximately 500,000 ng/L". It is tempting to read the five-fold gap as a performance ranking, or to treat 500,000 ng/L as the ceiling every new troponin assay should now match.

The short answer is no. Each number is the upper end of a study designed for one submission. Neither ranks the two assays, and neither tells you how much excess antigen either assay can tolerate. The Roche claim covers cardiac troponin T (cTnT) in lithium heparin plasma, measured on the cobas e 411 and cobas e 601 analyzers, with the hook point defined against the signal of the highest master calibrator. The Abbott claim covers cardiac troponin I (cTnI) in lithium heparin whole blood and plasma, measured with a single-use cartridge on the i-STAT Alinity instrument, with the decision rule defined against the highest manufacturer's working calibrator (MWC7). The analytes, specimen matrices, challenge materials, decision rules and platforms are all different, and the two clearances are nine years apart.

In a sandwich immunoassay, a high-dose hook (or prozone) effect occurs when so much antigen is present that capture and detection antibodies are each occupied by separate antigen molecules, fewer complete sandwiches form, and the signal falls. The risk the study addresses is that a very high sample produces a result that looks lower than it is. Both submissions discussed here deal with that risk the same general way: they spike samples well above the measuring range, run a dilution series and check that results stay above a defined threshold. The details of each step are where they part company.

Before either published claim can inform the design of a new 510(k) submission, or be cited in an IVDR performance evaluation, five fields have to be extracted and reconciled: the analyte, the specimen matrix, the challenge material, the decision rule that defines "no hook effect," and the platform and submission scope. The sections below walk through each submission in that order, using only the FDA-posted documents.

What K162895 Actually Claims: Elecsys Troponin T Gen 5 STAT

FDA's substantial equivalence letter for K162895 is dated January 18, 2017. The device was classified under 21 CFR 862.1215 (Class II, product code MMI), and the FDA database lists the submission as a Traditional 510(k). The predicate for the assay was Roche's Elecsys Troponin T, 4th generation STAT immunoassay (K051752). The indication is narrow: quantitative determination of cTnT in lithium heparin plasma, as an aid in the diagnosis of myocardial infarction, using the electrochemiluminescence immunoassay (ECLIA) on cobas system analyzers. FDA's decision summary records that the performance data were generated on the cobas e 411 and cobas e 601.

The test principle explains why platform scope matters. Biotinylated and ruthenium-labeled monoclonal cTnT antibodies form a sandwich with the analyte, and the complex is captured on streptavidin-coated microparticles. On the cobas e 411 the sandwich forms first and is captured during a second incubation, a two-step format. On the cobas e 601 sandwich formation and capture happen in the same incubation, a one-step format. The reagent is the same, but the reaction sequence is not.

The specimen scope also narrowed relative to the predicate. FDA's comparison table lists lithium heparin plasma for the Gen 5 STAT assay versus plasma and serum for K051752. The measuring range is 6–10,000 ng/L, with the upper end defined by the assay's linear range. FDA's decision summary reports detection limits by instrument: LoB 3 ng/L and LoD 5 ng/L on the cobas e 411, LoB 2.5 ng/L and LoD 3 ng/L on the cobas e 601, and LoQ 6.0 ng/L on both.

The hook study itself is described briefly. Two samples were spiked with analyte to high TnT concentrations. For each, a dilution series was prepared in low-TnT lithium heparin plasma and run on the cobas e 411 and cobas e 601. The summary defines the reported hook concentration as the analyte concentration whose signal is at least 10% above the highest master calibrator. The stated result: "No hook effect was seen up to 100,000 ng/L".

FDA's decision summary restates the claim in its own words: "A study was performed to support the claim that there was no hook effect up to 100,000 ng/L cTnT on both the cobas e 411 and cobas e 601." The named analyzers are part of the reviewed claim. The same memorandum records a separate statement that the cobas e 411 and cobas e 601 can perform a 1:10 dilution for samples that are out of range. That is a dilution claim, not a hook claim, and the two should be cited separately.

What K253051 Actually Claims: i-STAT hs-TnI on the Alinity System

FDA's decision date for K253051 is June 11, 2026. The FDA database lists Abbott Point of Care, Inc. as applicant, a receipt date of September 22, 2025, product codes MMI (21 CFR 862.1215) and JJE, and a Traditional 510(k). The predicate is the same cartridge on Abbott's earlier analyzer: the i-STAT hs-TnI Cartridge with the i-STAT 1 System (K240984). The intended use is quantification of cTnI in whole blood or plasma samples "in point of care or clinical laboratory settings". The site's point-of-care testing guide covers how that setting shapes the wider regulatory picture.

The measurement technology differs from Roche's at every level. The test is an enzyme-linked immunosorbent assay (ELISA) with electrochemical detection, performed in a single-use cartridge. Capture antibodies are coated on para-magnetic microparticles, and both capture and label antibodies sit on a biosensor chip inside the cartridge. The sample dissolves the reagents and the sandwich forms. Unbound sample and excess conjugate are then washed off the sensors, and an enzyme in the sandwich generates a product the chip detects electrochemically. Results are reported in about 15 minutes, and all fluid movement is driven by the instrument.

Calibration is handled differently too. The summary states that no calibration is needed by the end user because calibration is pre-set during cartridge manufacture, and that values are traceable to i-STAT's working calibrators prepared from human cardiac troponin-ITC complex (NIST SRM2921). Roche's assay, by contrast, is calibrated on the analyzer with a dedicated CalSet. The reportable range for the i-STAT hs-TnI cartridge is 2.9–1,000.0 ng/L for both whole blood and plasma.

The hook-effect study used venous whole blood and plasma collected with lithium heparin, spiked with recombinant human cardiac troponin ITC-complex and serially diluted to obtain cTnI levels up to approximately 500,000 ng/L. Samples were tested alongside MWC7, the highest-level calibrator, whose cTnI level is above the 1,000.0 ng/L top of the reportable range. The acceptance rule was that the measured results of the test samples were greater than that of MWC7. The conclusion: "Hook effect was not observed for the i-STAT hs-TnI test in the i-STAT hs-TnI cartridge with the i-STAT Alinity System using whole blood and plasma samples with cardiac troponin I concentrations up to approximately 500,000 ng/L."

Note what this rule tests. MWC7 already sits above the reportable range, so the question is whether a sample spiked to as much as 500 times the upper reportable limit still reads above an above-range calibrator. The summary does not claim the cartridge quantifies anything near 500,000 ng/L, it does not say how many samples were run, and it does not describe the shape of the dilution curve. It reports that, across the tested series, results did not fall below MWC7.

Side by Side: The Claim-Boundary Comparison Table

The table lines up the two submissions field by field. Each cell comes from the FDA-posted 510(k) summary, FDA decision summary or FDA database record for that submission. The last column says what the difference means for anyone trying to use the claims as precedent.

Two rows deserve more attention. First, the analyte row ends the numeric comparison on its own. cTnT and cTnI are different proteins, measured with different antibodies and reported through separate calibration hierarchies. Roche's values are traceable to its own 4th-generation assay; Abbott's are traceable to working calibrators prepared from a troponin-complex reference material. Abbott's summary also cautions that i-STAT control and calibration-verification values "may not be commutable with other methods." A ng/L figure from one assay is not a quantity of the same thing on the other.

Second, look at where each ceiling sits relative to its own measuring range. Roche's 100,000 ng/L is 10 times its 10,000 ng/L upper limit. Abbott's approximately 500,000 ng/L is about 500 times its 1,000.0 ng/L upper limit. Those ratios are arithmetic, not margins. Each decision rule uses a different reference point (a master-calibrator signal plus 10%, versus a working calibrator that is itself above the reportable range), and neither summary publishes its dilution curves. The ratios therefore do not show how close either assay came to a hook, and they cannot rank the assays any better than the raw numbers can.

Why the Claim Is Re-Established at Every Platform Step

Neither manufacturer's record treats a hook-effect claim as something a later device inherits. In each predicate chain reviewed here, the newer submission carries its own hook statement for its own configuration:

• Abbott, i-STAT 1 to i-STAT Alinity (K240984 → K253051). K240984, cleared January 3, 2025, covers the hs-TnI cartridge on the i-STAT 1 System. Its hook study uses the same design later reported for Alinity: lithium heparin venous whole blood and plasma, a recombinant human cardiac troponin ITC-complex spike, serial dilution, and comparison against MWC7. K253051 then reports a hook evaluation on the i-STAT Alinity System and names that system in its conclusion. The wording shifted as well. K240984 says hook effect was not observed "up to 500,000 ng/L"; K253051 says "up to approximately 500,000 ng/L". The public summaries do not explain why the newer one adds "approximately," so quote each one exactly.

• Roche, Gen 5 STAT to the biotin-modified Gen 5 (K162895 → K201441). FDA describes K201441, received June 1, 2020 and cleared September 21, 2021, as a "Modification of a previously cleared assay (k162895) to decrease interference to biotin." The reagent changes were a monoclonal biotin-scavenging antibody added to the reaction mix and a longer linker on the biotinylated capture antibody. The listed antibody epitopes are unchanged and the measuring range stays at 6–10,000 ng/L. Performance data were generated on the previously cleared cobas e 801 analyzer, and the decision summary again records that "A study was performed to support the claim that there was no hook effect up to 100,000 ng/L cTnT." The number matches K162895, but the submission reports a hook study for the modified reagent on a different analyzer. Unchanged epitopes did not stand in for that data. The site's guide to antibody clone lock and lot-to-lot bridging covers the wider reagent-change question.

• Across manufacturers, Roche as Abbott's predicate (K162895 → K191595). FDA's decision summary for Abbott's ARCHITECT STAT High Sensitivity Troponin-I (K191595) names the Elecsys Troponin T Gen 5 STAT (K162895) as predicate. The comparison table lists the differences openly: cTnI versus cTnT, and K2-EDTA plasma versus lithium heparin plasma. The ARCHITECT assay is a chemiluminescent microparticle immunoassay on the ARCHITECT i2000SR System with a measuring range of 3.5–5,000.0 ng/L, and FDA records that "The sponsor demonstrated that there is no hook effect with the assay up to 500,000 ng/L." The predicate relationship transferred neither the 100,000 ng/L figure nor the matrix.

Two lessons follow for predicate selection. First, in every pairing above the later device reports its own hook data, so do not plan to cite a predicate's hook number in place of your own study. Second, K191595 shows FDA finding substantial equivalence while the hook ceiling, the matrix and the measurand all differ from the predicate's. A hook number that differs from your predicate's is not, by itself, a barrier.

Where the Claim Lives After Clearance: Summary, Decision Memo, and IFU

A benchmarking team will meet the same claim in up to three public texts, each written for a different purpose and each worded a little differently:

1. The 510(k) summary. Prepared by the sponsor under 21 CFR 807.92 and posted by FDA. For both submissions here it holds the fullest public description of the hook study: specimens, spike, dilution scheme and decision rule.

2. FDA's decision summary. Written by FDA, shorter in this case, and sometimes explicit about scope. For K162895 it restates the claim as applying "on both the cobas e 411 and cobas e 601", which pins the claim to named instruments.

3. The instructions for use (IFU). Manufacturer labeling written for laboratory users. Shorter still, and it can change with each revision.

Abbott's IFU shows how the wording compresses. The UK-English edition of the i-STAT hs-TnI cartridge IFU (Art 798049-01A, revision dated April 17, 2025) covers the study in three short sentences: whole blood and plasma samples spiked to high cTnI levels (up to 500,000 ng/L), and "No hook effect was detected in samples up to 500,000 ng/L." It does not name the recombinant ITC-complex spike or the MWC7 rule. That revision also predates the June 2026 K253051 clearance. It shows how the labeling words the claim, not what FDA cleared for the Alinity configuration.

Hook Effect Is Not the Only High-Dose Boundary

A clean hook result does not cover every way a high or unusual sample can mislead. The hook study tests one thing: antigen excess in spiked samples. Interference studies test others, and the same K162895 summary documents several boundaries the hook claim does not address:

• Human anti-mouse antibodies (HAMA). Roche reports: "Interference of approximately 10% was seen with HAMA concentrations ≥ 322 µg/L." The labeling table in the same summary prints the figure as 322 µg/mL, while the result sentence and the HAMA stock concentration (805 µg/L) use µg/L. That is a reason to quote the study result sentence rather than a table transcription. Either way, the hook claim says nothing about HAMA.

• Hemoglobin. The labeled no-interference limit for hemoglobin is 0.1 g/dL, based on recoveries within ±10% of samples without the interferent. The hook claim does not extend to hemolyzed samples beyond that limit.

• Biotin. K162895 labels the streptavidin–biotin assay with no interference up to 20 ng/mL biotin. FDA's K201441 decision summary lists the modified reagent's tolerance as no interference up to 1,500 ng/mL. That reagent change was the purpose of K201441, and the submission came with a new hook statement, as described above.

Both summaries report the hook study as one part of a wider analytical performance package, alongside precision, linearity, detection limits, interference and cross-reactivity. A high hook ceiling does not make up for a narrow interference margin, and a wide interference margin does not make up for an unstudied hook range.

A Five-Field Checklist Before Citing Any Hook-Effect Claim

Turn the comparison into a repeatable step. Before a competitor or predicate hook-effect concentration goes into a design input, protocol rationale or submission table, record these five fields from the primary document, quoting rather than paraphrasing:

1. Analyte and calibration hierarchy. Name the measurand exactly (cTnT, cTnI or a defined complex) and note what the assay's values are traceable to. If the analyte differs from yours, the number is context, not a benchmark.

2. Specimen matrix. List every specimen type and anticoagulant the hook study used and compare it with the cleared indication: serum, lithium heparin plasma, K2-EDTA plasma or whole blood. A plasma-only study does not cover whole blood, and the reverse.

3. Challenge material. Record what was spiked (recombinant protein, a named complex or native high-concentration material) and whether the hook section itself says so. If it does not, as in K162895, write "not stated" and do not borrow the answer from another section.

4. Decision rule. Copy the criterion that defines "no hook effect": a signal margin over a master calibrator, a result above an above-range working calibrator, or something else. Without the rule, the ceiling has no meaning.

5. Platform and submission scope. Note the analyzer or analyzers, reaction format, reagent version, K-number and document date. If any of these differ from your device, plan your own study on your configuration. The records above show sponsors doing exactly that at each step.

Applied to the two submissions in this article, fields 1, 4 and 5 differ outright, field 2 only partly overlaps (both cover lithium heparin plasma, only Abbott covers whole blood), and field 3 cannot be completed for Roche. The checklist ends where the table did: two valid claims and no numeric comparison. The same logic as a decision flow:

flowchart TD
    A["Hook-effect claim found in a cleared 510(k)"] --> B{"Same analyte as your assay?"}
    B -- "No, e.g. cTnT vs cTnI" --> X["Context only: not a numeric benchmark"]
    B -- "Yes" --> C{"Same specimen matrix?"}
    C -- "No" --> X
    C -- "Yes" --> D{"Challenge material disclosed?"}
    D -- "No" --> D1["Record the disclosure gap"]
    D1 --> E
    D -- "Yes" --> E{"Decision rule comparable to your planned rule?"}
    E -- "No" --> X
    E -- "Yes" --> F{"Same platform and reagent version?"}
    F -- "No" --> G["Design precedent only: run your own study"]
    F -- "Yes" --> H["Cite within its stated scope"]

Limits of This Comparison

• Summary-level evidence only. Everything here comes from FDA-posted 510(k) summaries, FDA decision summaries, FDA database records and one manufacturer IFU. Dilution curves, raw signals and replicate data are not published in these documents, so no claim boundary could be recomputed.

• Roche's undisclosed spike. The K162895 hook section does not name its challenge material, and this article does not infer one.

• Different eras and standards. K162895 (2017) cites CLSI EP5-A2, EP6-A and EP17-A2, plus EP7-A for drug interference. K253051 (2026) cites EP05-A3, EP06-Ed2, EP17-A2, EP35 and EP07-ED3. Some wording differences may reflect the review conventions of each period rather than study design. These are the editions the submissions cite, not a statement of current FDA expectations.

• Narrow sample. Only the two headline submissions and three directly linked ones (K240984, K201441 and K191595) were reviewed. Other cleared troponin assays were not surveyed.

• Regulatory evidence, not clinical guidance. This is an analysis of what clearance documents claim. It is not clinical advice, says nothing about either assay's clinical performance, and cannot speak to how often hook effects occur in practice; reported events cannot be inferred from clearance records.